Regeneron Pharmaceuticals, Inc. (REGN) Q2 2014 Earnings Results

Regeneron Pharmaceuticals Beats on EPS, Stock Up 2.38%

Regeneron's earnings report showed a solid EPS performance, which contributed to a 2.38% increase in the stock price. The positive surprise in EPS indicates that the company is managing its costs effectively. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$2.47	N/A	+6.01%

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook on earnings performance. However, they did not provide specific guidance for future quarters.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

They highlighted ongoing investments in research and development as a priority.

Regeneron Pharmaceuticals Beats on EPS, Stock Up 2.38%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Beats on EPS, Stock Up 2.38%

Key numbers

Management commentary